References
- Estey E, Dohner H. Acute Myeloid Leukaemia. The Lancet 2006; 368(9550): 1894.
- Bruserud O, Gjertsen BT, Foss B, Huang TS. New strategies in thetreatment of acute myelogenous leukaemia (AML): in vitro culture of AML cells — the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 2001; 19: 1.
- Campos L, Oriol P, Sabido O, Guyotat D. Simultaneous expression of P-glycoprotein and Bc1-2 in acute myeloid leukemia blast cells. Leuk Lymphoma 1997; 27(1-2): 119–125.
- Nara N, Chen GJ, Murohashi I et al. The in vitro growth patternsand drug sensitivities of leukemic blast progenitors among the subtypes of acute myelocytic leukemia. Exp Hematol 1992; 20(7): 904–908.
- Boutannat J, Muirhead KA, Barbier M, Moussequ M, Ronot X, Seigneurin D. PKH26 probe in the study of the proliferation of chemoresistant leukemic sublines. Anticancer Res 1998; 18(6A): 4243–4251.
- Sargent JM. The use of the MTT assay to study drug resistance infresh tumour samples. Recent Results Cancer Res 2003; 161: 13–25.
- Norgaard JM, Jensen PD, Bendix K, Clausen N, Palshof T. Relevance of in vitro leukaemia cell survival to short and long term clinical outcome in AML. Leuk Lymphoma 1999; 32(3-4): 327–337.
- Yates J, Gildewell O, Wiernik P et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute mye-locytic leukemia: a CALBG study. Blood 1982; 60(2): 454–462.
- Mayer RJ, Davies RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. The New Engl J Med 1994; 331(14): 896–903.
- Salem M, Delwel R, Touw I, Mahmoud L, Lowenberg B. Human AMLcolony growth in serum-free culture. Leuk Res 1988; 12(2): 157–165.
- Fotakis G and Timbrell JA. In vitro cytotoxicity assays: comparison of LDH, neutral red, MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride. Toxicol Lett 2006; 160(2): 171.
- Sun J, Wang L, Waring MA, Wanc C, woodman KK, Sjeil AG. Simple and reliable methods to assess hepatocyte viability in bioartificial liver support system matrices. Artif Organs 1997; 21(5): 408.
- Lee ST, Jang JH, Min YH, Hahn JS, Ko YMT. AC133 antigen as a prognostic factor in acute leukemia. Leuk Res 2001; 25(9): 757–767.
- Bene MC, Bernier M, Casasnovas RO et al. Acute myeloid leukaemia MO: haematological, immunophenotypic and cytoge-netic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001; 113(3): 737–745.
- Saxena A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998; 58(4): 278–284.
- Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in porgress. Laboratory Investigation 2006; 86: 1203.
- Fujimoto H, Sakata T, Hamaguchi Y, Shiga S, Tohyama K, Ichiyama S et al. Flow cytometric method for enumeration and classification of reactive immature granulocyte populations. Cytometry (Communications in Clinical Cytometry) 2000; 42: 371.
- Auewarakul CU, Promsuwicha O, U-Pratya Y, Pattanapanyasat K, Issaragrisil S. Immunophenotypic profile of adult acute myeloid leukemia (AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol 2003; 21(3): 153.
- Moulding D, Quayle JA, Stringer RE, Hart CA, Edwards SW. Regulation of Neutrophil Apoptosis by Sodium Butyrate. Biologicals 1996; 24: 301.
- Kabral A, Bradstock KF, Grimsley P, Favaloro EJ. Immunophenotype of clonogenic cells in myeloid leukaemia. Leuk Res 1988; 12(1): 51.
- Ross DW. Leukemic cell maturation. Arch Pathol Lab Med 1985; 109(4): 309.
- Prus E, Fibach E. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relation-ship with cell differentiation. Leuk Lymphoma 2003; 44(4): 691.
- Moore MAS, Dorn DC, Schuringa ii, Chung KY, Morrone G. Constitutive activation of F1t3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Experimental Hematol 2007; 35: 105.